Author: Hybrid_49

Development of a More Sustainable 2nd Generation Route to Peptide-Maleimidocaproyl MonoMethyl Auristatin F (mcMMAF)-the Cytotoxic Payload for Blenrep®, A Novel Antibody Conjugate Drug (ACD) for the Treatment of Multiple Myeloma

• October 24, 2024
• Hybrid_49
• Industry Awards
• No Comments on Development of a More Sustainable 2nd Generation Route to Peptide-Maleimidocaproyl MonoMethyl Auristatin F (mcMMAF)-the Cytotoxic Payload for Blenrep®, A Novel Antibody Conjugate Drug (ACD) for the Treatment of Multiple Myeloma

Continue reading